Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 SNBIF | Healthcare | $10.11 | 0.00 | $414.42M | -17.65 | ― | Hold |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SNBIF | SanBio Co | 10.11 | -33.97 | -77.07% |
| Name | Price | % Change | |
|---|---|---|---|
| SNBIF | $10.11 | -77.07% |
SanBio Co ( ($JP:4592) ) has shared an update. SanBio Co., Ltd., a biopharmaceutical company listed on the TSE Growth market, is expanding from a predominantly research and development-driven model
An update from SanBio Co ( ($JP:4592) ) is now available. SanBio Company Limited has released its financial results for the second quarter of the fiscal year ending January 31,
SanBio Co ( ($JP:4592) ) has shared an announcement. SanBio reported that its second-quarter results for the fiscal year ending January 31, 2027 showed a significantly narrower loss than previously
SanBio Co ( ($JP:4592) ) just unveiled an announcement. SanBio Co., Ltd., listed on the Tokyo Stock Exchange, is a biotechnology firm specializing in regenerative medicine and advanced cell-based therapies.
SanBio Co ( ($JP:4592) ) has shared an announcement. SanBio Co., Ltd. reported notable non-operating items in the second quarter of its fiscal year ending January 31, 2027, including a
The latest update is out from SanBio Co ( ($JP:4592) ). SanBio has been informed that Minaris Advanced Therapies LLC will close its Mountain View, California, U.S. facility, which currently
SanBio Co ( ($JP:4592) ) has issued an announcement. SanBio Co. reported that in the first quarter of the fiscal year ending January 31, 2027, it booked non-operating income of
Jefferies upgraded SanBio (SNBIF) to Hold from Underperform with a price target of 1,200 yen, down from 1,500 yen. Following the sales guidance of Akuugo released in May, the firm
SanBio Co ( ($JP:4592) ) just unveiled an announcement. SanBio reported no operating revenue for the three months ended April 30, 2026, and narrowed its net loss attributable to owners
SanBio Co ( ($JP:4592) ) has shared an update. SanBio has secured National Health Insurance price listing in Japan for AKUUGO Suspension for Intracranial Implantation, a cell therapy for improving
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| SNBIF | Dec 15, 2026TBA | $414.42M | $-0.10 | $763.81K | -1.38 | -17.65 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
